Shelley Metzenbaum: A Life of Purpose, Reframed by ALS

March 19, 2026

Share this —

For decades, Shelley Metzenbaum has worked to help government and nonprofits better serve the people they aim to serve.

Her career spans all levels of public service. From leading efforts at the U.S. Office of Management and Budget to improve the use and communication of government goals, data, analysis, and research findings to achieve better results, to leading The Volcker Alliance, to many other roles in government, non-profits, and academia, Shelley has dedicated her life to making the world a better place for everyone, especially those most disadvantaged.

Then ALS entered her life. And the questions and challenges she faced every day changed.

“I didn’t know anything about ALS,” she said. “I knew Stephen Hawking. That was pretty much it.”

What followed was not just a diagnosis, but a reckoning with how health systems communicate, how research priorities are set, and how much of living with disease happens far outside the walls of a clinic.

When Measurement Matters

Shelley has long distinguished between measuring government performance and actually using

data to make things better.

“One of the problems we’ve had in government,” she explained, “is we got people to measure, but we don’t have them using data to inform where they focus and to find ways to improve.

That lens didn’t automatically transfer to ALS. At first, she said, she wasn’t thinking about how the system should work. She was just trying to understand what was happening to her body.

She described the earliest signs as subtle and strange. Her arms felt “weird.” Not painful, not numb. Just wrong. Then came difficulty reaching high shelves, followed by a misdiagnosis and surgery that left her dominant arm dramatically weaker.

Eventually the verdict came in: ALS.

“My reaction was, ‘How do I deal with this?’” she said.

The Moment That Could Have Gone Very Differently

Shelley is quick to acknowledge how lucky she has been. Living near Boston gave her access to world-class care, and she describes moments of extraordinary humanity within the medical system.

She recalled meeting Dr. James Berry from Mass General, with whom she had a consult on an island near Martha’s Vineyard.

“He meets me in his shocking pink shorts and his shocking pink shoes while he was on vacation,” she said, laughing. “And I fall in love, because he’s just so lovable. Plus, of course, knowledgeable and helpful.”

He spent hours with her and her daughters, followed up within a day, and connected her to a level of nursing support she hadn’t experienced elsewhere. That follow-through mattered.

“The nursing capacity is remarkable,” she said simply.

She also recalled the wisdom of Dr. Seward Rutkove at Beth Israel, who so wisely ordered the right tests to enable her initial ALS diagnosis.

But Shelley is clear that her experience is not universal. She worries about what happens to people diagnosed in places without those resources, or without the social capital to navigate a fragmented system.

“I wonder how to get that kind of luck to others,” she said.

Living Where the Research Isn’t

As the disease progressed, Shelley became increasingly frustrated by the gap between what research measures and what daily life actually demands.

“One of the biggest challenges is adapting,” she said.

She talked about the difficulty of dressing at the beginning, end, and throughout the day because of the continually waning function of her arms. About the exhaustion of feeding herself. About adaptive tools that exist but are expensive or inaccessible.

“There is a robot feeder called Obi” she said. “It’s $8,000 plus. Medicare doesn’t cover it. Nor will my supplemental health insurance.” She is appreciative that there are organizations that can sometimes help individuals borrow an Obi. After much outreach, Easterseals Massachusetts is now lending her a machine.

To Shelley, this is not peripheral. It is central.

She questioned why innovation challenges like the Ice Bucket Challenge couldn’t be reimagined to focus on adaptive technology as well as the causes and searches for effective treatments.

Tools that would help people with ALS, but might also help people with arthritis, Parkinson’s, MS.

“Don’t just limit yourself to the medicine,” she said, encouraging bright minds in science and research to be considering innovation from all angles.

Rethinking What Progress Means

Shelley also spoke candidly about how treatments are communicated.

When she was prescribed riluzole, she was told it offered about a 10% improvement.

“I looked at the chart and I’m like, OK, what does this mean?” she said. “Does this mean I’ll be 10% better over time starting now? Or does it mean you’re going to extend my life 10%?”

She was clear about the distinction.

“I don’t want to live 10% longer if I have no functionality,” she said. “I’ll take 10% better right now.”

For someone who has spent her career thinking about performance metrics, this ambiguity wasn’t academic. It was existential.

Purpose as a Survival Strategy

Despite everything, Shelley does not describe herself as bitter or defeated. She describes herself as focused.

“I chose to live what I call a purposeful life,” she said. “I won’t get it all done. I wasn’t going to get it all done even if I lived to 100.”

She now thinks of herself as having three jobs: managing her medical care, managing caregiving, and doing the work she still cares deeply about. Much of it pro bono. All of it aligned with her lifelong mission to improve how systems function to make the world a better place for everyone.

When things feel overwhelming, she said she reminds herself that spiraling helps no one. “It hurts you,” she said. “So don’t let yourself go there.”

She also speaks with gratitude about her family, her caregivers, her friends, and the kindness of strangers. About one daughter making time for her to FaceTime with her grandson every morning. About her other daughter taking her on adventures, going to see Dancing with the Stars and soon a trip to Nashville and New Orleans.

“Have fun and make a difference,” she said. “Figure out what’s fun for you and focus on that. Figure out what you can do to help others, prioritize, and work on that.”

The Message She Wants to Leave

If Shelley could redesign one part of the ALS journey, it wouldn’t be just a drug pipeline or a policy lever. It would also be the flow of information. Making it easier to find what you need.

Easier to learn from others without being overwhelmed. Easier to focus on living, not just managing decline. She is enormously grateful to Compassionate Care and the ALS Association for the information and support they have given her, to Target ALS for boosting relevant research, and to her PT and OT providers. She is hopeful that evolving research will continually make life easier for people living with ALS.

And if there’s one thing ALS has clarified for her, it’s this: time sharpens priorities.

“I thought I was going to live to my late 90s,” she said. “I have less time. But I never wanted to be old and decrepit. Now, I’m young and decrepit.”

She laughed, then added, without self-pity, “I’ve had a wonderful life.” And she’s still very much living it.